Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats.

Hepatocellular carcinoma (HCC) is a fatal oncogenic disorder with few therapeutic options. Novel therapeutic strategy with combination of a selective CDK4/6 inhibitor palbociclib (PAL) with a tyrosine kinase inhibitor (TKI) sorafenib (SOR) is reported to impair tumour growth and significantly increased survival in various preclinical models of HCC. In the current work a sensitive and rapid UHPLC-QTOF-MS method was established for the concurrent quantification of PAL and SOR in rat plasma using ibrutinib as internal standard (IS).

An assessment of the impact of green tea extract on palbociclib pharmacokinetics using a validated UHPLC-QTOF-MS method.

Green tea extracts (GTE) has been reported to be a kinase inhibitor and modulator for various drug metabolizing enzymes. It may give synergetic antioncogenic effect, but with a possibility of pharmacokinetic interactions with various co-administered anticancer agents like palbociclib (PAL), a selective inhibitor of CDK-4/6 primarily metabolized by CYP3A enzyme. To explore the impact of GTE on PAL pharmacokinetics in Sprague-Dawley rats, a rapid and sensitive UHPLC-QTOF-MS method was established.